阿尔茨海默病临床试验联盟 (ACTC)-猫眼课题宝

阿尔茨海默病临床试验联盟 (ACTC)

批准号：

10435786

负责人：

Paul S. Aisen

金额：

$23.05万

依托单位：

UNIVERSITY OF SOUTHERN CALIFORNIA

依托单位国家：

美国

项目类别：

财政年份：

2017

资助国家：

美国

项目状态：

已结题

起止时间：

2017-12-02 至 2023-06-30

来源：

https://reporter.nih.gov/project-details/10435786

关键词：

Agreement Alzheimer&apos s Disease Alzheimer&apos s disease related dementia Amyloid Autopsy Bioinformatics Biological Assay Biological Markers Biometry Blood Clinical Clinical Investigator Clinical Research Clinical Trials Clinical Trials Network Cognitive Collaborations Combined Modality Therapy Communities Computer software Contracts Data Data Analyses Disease Down Syndrome Early intervention trials Elderly Enrollment Fostering Funding Image Individual Informatics Infrastructure Institutes Institutional Review Boards Intervention Leadership Magnetic Resonance Imaging Medical Methods Monitor Network Infrastructure Neurodegenerative Disorders Outcome Outcome Measure Outcome Study Participant Pathology Patient Recruitments Phase Play Population Population Heterogeneity Positron-Emission Tomography Prevention trial Primary Prevention Probability Procedures Protocols documentation Readiness Research Research Design Research Personnel Resources Risk Role Sampling Secondary Prevention Secure Site Specimen Therapeutic TimeLine Tissues United States National Institutes of Health base biobank clinical care cohort cooperative study data management data sharing design drug development effective therapy electronic data capture system eligible participant experience innovation instrument interest meetings mild cognitive impairment neurodegenerative dementia neuroimaging neuropathology next generation novel operation participant retention phenotypic data polygenic risk score pre-clinical prediction algorithm programs public-private partnership recruit retention rate tau Proteins trial design

中文摘要

翻译

有了这个补充，我们请求支持扩大NIH包括试验准备

英文摘要

With this supplement, we request support to expand the NIH INCLUDE Trial-Ready Cohort-Down Syndrome (TRC-DS) project, which as part of the R61 phase (cohort) seeks to enroll 120 participants with DS, in advance of the R33 phase placebocontrolled clinical trial of an anti-amyloid therapeutic in this population. The specific aims of the TRC-DS project include building a readiness cohort that will both inform the design of a clinical trial as well as provide interested and eligible participants while collecting a rich set of participant-level phenotypic data. The Institute Jérôme Lejeune is a preeminent center in the world for clinical care of individuals with DS, including older adults with DS-related AD. Adding this site to the ACTC-DS network for participation in the TRC-DS project will further advance the impact and diversity of the project and establish a strong collaboration with an outstanding research team.

期刊论文(0)

专著(0)

科研奖励(0)

会议论文